CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma

December 2, 2018, University of Chicago Medical Center

An international phase-2 trial of a CAR-T cell therapy—to be published on-line Dec. 1 in the New England Journal of Medicine (and presented at the ASH annual meeting in San Diego)—found that 52 percent of patients responded favorably to the therapy; 40 percent had a complete response and 12 percent had a partial response. One year later, 65 percent percent of those patients were relapse-free, including 79 percent of complete responders. The median progression-free survival 'has not been reached.'

In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). They found that 52 percent of those patients responded favorably to the therapy. Forty percent had a complete response and 12 percent had a partial response.

Sixty-five percent of those patients—recruited from 27 sites in North America, Europe, Australia and Asia—were relapse free one year later, including 79 percent of the complete responders. The median progression-free survival for patients in this trial, known as JULIET; NCT02445248, "has not been reached," the authors note.

This compares favorably with earlier studies based on chemotherapy. The retrospective SCHOLAR-1 study, published in 2017, found that only seven percent of patients with refractory DLBCL had a complete response. The median overall survival was a mere 6.2 months. "Outcomes were consistently poor across patient subgroups and study cohorts," the SCHOLAR-1 authors noted.

More promising data from the JULIET trial "led to the Food and Drug Administration's approval May 1, 2018 of tisagenlecleucel for treatment of DLBCL," said study co-author Michael Bishop, MD, Professor of Medicine and Director of the Cellular Therapy Program at the University of Chicago Medicine. "Our current results are a promising sign of the potential for long-term benefit."

Scott McIntyre, the first patient to receive CAR-T cell therapy for stage 3 DLBCL at the University of Chicago, was pleased to learn about the study results. He is now 30 months post treatment and has had no sign of recurrence. He still gets a transfusion of antibodies every two months to protect him from the risk of infection that comes with the loss of his normal B . But the South Bend, Indiana native quickly returned to his job and seldom misses a Notre Dame football game. He just returned from watching the undefeated team beat the University of Southern California.

The JULIET trial, based at the University of Pennsylvania, is a single-arm, open-label, global study in adults with relapsed or refractory DLBCL. Patients who were enrolled had received at least two previous lines of therapy.

The treatment process is complicated. The care team takes blood from the patient, extracts T-cells and returns everything else. The T cells were shipped to Novartis' Morris Plains facility in New Jersey. The team there modified the T lymphocytes, enabling them to find disease-causing B cells that display a surface protein called CD19 and destroy them.

Once the T cells are returned to the hospital and re-infused into the patient, they multiply rapidly, producing millions of offspring. They quickly launch a vigorous assault on cells that display CD19, leading to the rapid destruction of cancerous cells.

The process, a form of immunotherapy, can have severe but generally self-limited side effects. The most common adverse event is cytokine release syndrome (58 percent), which causes severe flu-like symptoms such as fevers, swelling and low blood pressure. It can also cause neurologic effects such as delirium, but physicians have learned how to control these side effects. No deaths in this trial were attributed to the treatment.

McIntyre experienced mild cytokine release syndrome and some neurologic effects, but responded quickly to drugs designed to limit these side effects.

"The median progression-free survival has not been reached for complete responders," the authors wrote. The probability of survival at month 12 "was 90 percent among complete responders."

"Overall, this is extremely exciting," Bishop said. "Relapses after 12 months are infrequent. Our first patient, treated in May 2016, has been back at work for two and a half years. This trial demonstrates that CAR-T cell therapy can provide a high rate of durable responses."

The FDA's approval of tisagenlecleucel in patients with relapsing or refractory DLBCL is based on the phase-2 JULIET clinical trial, the first multi-center global registration study for Kymriah in adult patients with DLBCL. JULIET is the largest study examining a CAR-T therapy in DLBCL. It has enrolled from 27 sites in 10 countries across the US, Canada, Australia, Japan and Europe, including: Austria, France, Germany, Italy, Norway and the Netherlands.

Explore further: Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma

More information: Stephen J. Schuster et al, Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma, New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1804980

Related Stories

Global trial shows CAR T therapy can lead to durable remissions in non-Hodgkin's lymphoma

December 2, 2018
In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients ...

Global CAR T therapy trial shows high rates of durable remission for NHL

December 10, 2017
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) ...

FDA approves CAR T therapy for large B-cell lymphoma

May 1, 2018
The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...

FDA approves new targeted drug for leukemia

November 28, 2018
The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine ...

Immunotherapy may become new first line treatment in some metastatic colorectal cancers

October 22, 2018
Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the ...

First multicenter trial; CAR T-cell immunotherapy effective for lymphoma

December 6, 2016
A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising ...

Recommended for you

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.